TABLE 6.
PROGRESSION-FREE SURVIVAL BY LINE OF TREATMENT AND BY TREATMENT REGIMEN EMPLOYED
| Line of Treatment | N | Progression-Free Survival (months; 95% confidence interval) |
p-value |
|---|---|---|---|
| Line 11 | 69 | 6.3 (4.9–7.7) | |
| Oxaliplatin-based | 61 | 6.4 | 0.63 |
| Irinotecan-based | 6 | 5.4 | |
| 5-FU2-based | 2 | 4.6 | |
| Line 2 | 58 | 2.5 (1.8–3.0) | |
| Oxaliplatin-based | 7 | 3.0 | 0.18 |
| Irinotecan-based | 39 | 3.0 | |
| 5-FU2-based | 4 | 3.1 | |
| Clinical trial | 4 | 3.6 | |
| Other | 4 | 1.7 | |
| Line 3 | 31 | 2.5 (1.0–4.2) | |
| Oxaliplatin-based | 5 | 3.1 | 0.19 |
| Irinotecan-based | 8 | 3.1 | |
| 5-FU2-based | 7 | 6.1 | |
| Clinical trial | 11 | 3.7 | |
| Other | 8 | 1.6 |
1
Two patients were too ill at presentation to receive systemic therapy.
2
5-fluorouracil without oxaliplatin or irinotecan.